Kareus Therapeutics discovers and develops novel small molecule as mono- or combination therapy for the unmet treatment of age-related and chronic diseases.

Our current focus is on Alzheimer's, Cardiovascular, Metabolic and Inflammatory diseases, which are areas of our core expertise.

Our discovery strategy is to target molecular and gene expression pathways using our proprietary KARLECT chemistry and BEND biology platforms. Our management team’s proven track record and recognized leadership helps propel molecules from exploratory through milestone discovery phases.

Our business strategy is to form early strategic alliances with Pharmaceutical companies, which have the complementary skills to maximize the business and therapeutic potential of our molecules.